An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

@article{Kennedy2003AnAM,
  title={An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.},
  author={Adam D. Kennedy and Michael D. Solga and Theodore A. Schuman and Amos W Chi and Margaret A Lindorfer and William M. Sutherland and Patricia L. Foley and Ronald P Taylor},
  journal={Blood},
  year={2003},
  volume={101 3},
  pages={1071-9}
}
We investigated deposition of the complement protein fragment C3b and its breakdown products (collectively designated as C3b(i)) on CD20-positive cells treated with rituximab (RTX) in the presence of normal human serum (NHS). Radioimmunoassay (RIA) demonstrates that about 500 000 C3b(i) molecules deposit per cell, and fluorescence microscopy reveals that C3b(i) colocalizes with bound RTX. Use of mAb 3E7, specific for C3b(i) bound to substrates, enhances C3b(i) deposition; > 1 million C3b(i… CONTINUE READING
58 Citations
59 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Therapeu - tic activity of humanized anti - CD 20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIa gene

  • G Cartron, L Dacheux, G Salles
  • Blood
  • 2002

Similar Papers

Loading similar papers…